title: Lower plasma pantoprazole level predicts Helicobacter pylori treatment failure in patients with type 2 diabetes mellitus.
abstract: OBJECTIVE
  We aimed to compare the plasma pantoprazole level (PPL) between patients with type 2 diabetes mellitus and non-diabetic patients during Helicobacter pylori (H. pylori) eradication treatment and to explore the role of PPL in predicting the treatment success rates.
  
  
  METHODS
  This study included 40 diabetic and 40 non-diabetic treatment-naive H. pylori-infected patients. Bismuth-based standard quadruple treatment for H. pylori eradication was used for 14 days in both groups. PPL was measured using the square-wave voltammetry method.
  
  
  RESULTS
  H. pylori eradication rate (60.0% vs 87.5%, P = 0.005) and PPL (0.25 ± 0.03 μg/mL vs 0.34 ± 0.03 μg/mL, P < 0.001) was significantly lower in the diabetic group compared with the controls. Patients with treatment failure had lower PPL than those with successful treatment (P < 0.001). The receiver operating characteristics curve demonstrated that PPL had a significant predictive value for the outcome of H. pylori eradication.
  
  
  CONCLUSIONS
  Type 2 diabetic patients had lower PPL than the non-diabetic controls, which led to their lower H. pylori eradication rates.
authors.affiliation: Department of Gastroenterology, Kırıkkale University Faculty of Medicine, Kırıkkale, Turkey.
authors.forename: Ferdane
authors.initials: F
authors.lastname: Sapmaz
authors.affiliation: Department of Gastroenterology, Kırıkkale University Faculty of Medicine, Kırıkkale, Turkey.
authors.forename: Ismail H
authors.initials: IH
authors.lastname: Kalkan
authors.affiliation: Department of Analytical Chemistry, Faculty of Pharmacy, University of Hacettepe, Ankara, Turkey.
authors.forename: Incilay
authors.initials: I
authors.lastname: Suslu
authors.affiliation: Department of Endocrinology and Metabolism, Kırıkkale University Faculty of Medicine, Kırıkkale, Turkey.
authors.forename: Hüseyin
authors.initials: H
authors.lastname: Demirci
authors.affiliation: Department of Pathology, Kırıkkale University Faculty of Medicine, Kırıkkale, Turkey.
authors.forename: Pinar
authors.initials: P
authors.lastname: Atasoy
authors.affiliation: Department of Gastroenterology, Kırıkkale University Faculty of Medicine, Kırıkkale, Turkey.
authors.forename: Sefa
authors.initials: S
authors.lastname: Guliter
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000097:blood* / Q000627:therapeutic use; D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D004359:Drug Therapy, Combination; D005260:Female; D016481:Helicobacter Infections / Q000150:complications / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D008297:Male; D008795:Metronidazole / Q000627:therapeutic use; D008875:Middle Aged; D009942:Organometallic Compounds / Q000627:therapeutic use; D000077402:Pantoprazole; D011237:Predictive Value of Tests; D054328:Proton Pump Inhibitors / Q000097:blood* / Q000627:therapeutic use; D012372:ROC Curve; D013752:Tetracycline / Q000627:therapeutic use; D017211:Treatment Failure
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D009942:Organometallic Compounds; D054328:Proton Pump Inhibitors; D008795:Metronidazole; D000077402:Pantoprazole; D013752:Tetracycline; C002791:bismuth tripotassium dicitrate
keywords: eradication; plasma pantoprazole level; type 2 diabetes mellitus